Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Dexamethasone

13 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Supportive Care

VICCPED1570

04/28/2016

A phase III, randomized, placebo-controlled clinical trial to study the efficacy and safety of MK-0517/fosaprepitant and ondansetron versus ondansetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric subjects receiving emetogenic chemotherapy

Treatment

VICCTHO15117

05/19/2016

A Phase 2 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line Treatment of Patients with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Carcinoma (TRINITY)

Treatment

COGAAML1331

04/28/2016

A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

Treatment

COGAALL1331

02/01/2016

Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Treatment

VICCHEM15112

01/11/2016

A Phase 1/2 Open-label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed/Refractory Multiple Myeloma

Treatment

VICCHEM14131

11/17/2015

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma

Treatment

VICCHEMP1558

10/09/2015

A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Treatment

VICCHEM1437

09/29/2015

A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age

Treatment

COGAALL1231

05/13/2015

A Phase III Randomized Trial Investigating Bortezomib NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Treatment

ECOGTHOS1400

04/02/2015

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

Treatment

COGANHL12P1

10/20/2014

A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117

Treatment

VICCHEM1146

08/14/2012

Ofatumumab in Combination with High Dose Cytarabine Chemoimmunotherapy for Patients with Newly Diagnosed Mantle Cell Lyjmphoma

Treatment

COGAALL1131

04/05/2012

A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND #73789, NSC# 606869) in the Very High Risk Stratum